We aim to provide evidence-based guidance on best clinical practice in the provision, monitoring and support of pre-exposure prophylaxis (PrEP) for the prevention of HIV acquisition. The guidelines include:
(i) Guidance on risk assessment prior to PrEP;
(ii) Baseline assessment;
(iii) Dosing schedules;
(v) Supporting adherence;
(vi) Buying generic PrEP; and
The guidelines are aimed at clinical professionals directly involved in, and responsible for, HIV prevention, and at community advocates and organisations responsible for supporting HIV prevention strategies in those at risk of HIV acquisition.
A detailed review of the evidence base is included in Section 4. Sections 5 to 7 are intended to offer practical guidance in risk assessment, starting PrEP, ongoing management while on PrEP and stopping PrEP.
Comments received by the BHIVA Secretariat during the public consultation process
Comments received from the BHIVA Executive Committee and Guidelines Subcommittee following revision after the web consultation
Declaration of interests
Declaration of interests from writing group members
These guidelines do not have a BHIVA non-technical summary, as many resources are already available. We suggest:
(NB These are links to external sites for which BHIVA has no responsibility)
Michael Brady (Chair), Alison Rodger (Chair), David Asboe, Valentina Cambiano, Dan Clutterbuck, Monica Desai, Nigel Field, Justin Harbottle, Zahra Jamal, Sheena McCormack, Adrian Palfreeman, Mags Portman, Killian Quinn, Melinda Tenant-Flowers, Ed Wilkins, Ingrid Young
The guidelines are currently undergoing full review.